| Description |
5J-4 is a potent CRAC inhibitor. 5J-4 decreases the numbers of infiltrated mononuclear cell into the CNS, and significantly decreases the population of infiltrated CD4+ population. 5J-4 reduces the symptoms and delayed the onset of EAE (experimental autoimmune encephalomyelitis) in mouse model of inflammation[1].
|
| Related Catalog |
|
| In Vivo |
5J-4 reduces the production of IL-17 and decreases the expression of RORα and RORγt[1]. 5J-4 (2 mg/kg; i.p.; every alternate day for 30 days) reduces the symptoms and delayed the onset of EAE[1]. Animal Model: C57BL/6 mice (MOG35-55 peptide-immunized mice)[1] Dosage: 2 m/kg Administration: I.p., every alternate day for 30 days Result: Dramatically reduced the symptoms and delayed the onset of EAE and decreased the numbers of infiltrated mononuclear cell into the CNS, and significantly decreased the population of infiltrated CD4+ population.
|
| References |
[1]. Kim KD, et al. Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation. J Immunol. 2014 Jan 1;192(1):110-22.
|
